Daria V. Borsakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daria V. Borsakova has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Elena Ivanovna Sinauridze
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Ministry of Healthcare, Samora Machel Street, 1, GSP-7, Moscow 117198, Russia
5 shared publications - Fazoil I. Ataullakhanov
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Srednyaya Kalitnikovskaya Street, 30, Moscow 109029, Russia
3 shared publications - Anastasia Ignatova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
2 shared publications F. I. Ataullakhanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare
2 shared publications- I. B. Kumukova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia; “Kommunarka” Moscow Multidisciplinary Clinical Center of the Department of Health in Moscow; Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
2 shared publications - M. E. Plakhotnik
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Ministry of Health of Russia
2 shared publications
Latest Publications
- 1 July 2019
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology
- Vol. 13 (3) , 212-224
Ways to Increase the Activity of Glutamate Dehydrogenase in Erythrocyte-Bioreactors for the Ammonium Removal
— An increased blood ammonium concentration (hyperammonemia) is toxic to the central nervous system, so removing excess ammonium from the bloodstream is an important task. One of the solutions...
- 1 July 2019
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology
- Vol. 13 (3) , 212-224
Ways to Increase the Activity of Glutamate Dehydrogenase in Erythrocyte-Bioreactors for the Ammonium Removal
— An increased blood ammonium concentration (hyperammonemia) is toxic to the central nervous system, so removing excess ammonium from the bloodstream is an important task. One of the solutions...
- 19 February 2019
- Published by Wiley in Vox Sanguinis
- Vol. 114 (3) , 223-231
The pathogen‐reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases
Background: Transmission of pathogens through blood transfusion is still of great concern to clinicians, patients and blood providers. Pathogen reduction technologies (PRT) have been successfully applied for the treatment of labile blood components, such as plasma, platelets and whole blood (WB), which are now used in routine in many countries. We report the clinical evaluation of suspension of red blood cells (RBC‐S) derived from the WB treated with riboflavin and UV light (RF+UV).Study Design and Methods: Seventy paediatric patients (0·3–17·1 years old) suffering from different malignant disorders were recruited and assigned to two groups: the control group (C) received transfusions of γ‐irradiated RBC‐S. The experimental group (T) received RBC‐S derived from WB, treated with RF+UV. Clinical efficacy was evaluated during follow‐up periods by Hb and Ht increments, and needs for transfusion support. Safety was assessed through active surveillance, recording post‐transfusion reactions, anti‐erythrocyte's antibody formation, haptoglobin and serum potassium levels.Results: The clinical efficacy of RBC‐S in both groups was similar: mean post‐transfusion Hb concentration (101·6 ± 7·57 g/l vs. 100 ± 8·3 g/l; P = 0·43), and Ht level (28·5 ± 2·42% vs. 28·2 ± 2·7%; P = 0·66). Transfusion of pathogen‐reduced RBC‐S did not increase the frequency of transfusion reactions and did not induce an excessive immune response in the follow‐up period.Conclusion: Transfusion of RBC‐S, obtained from pathogen‐reduced WB, is a promising method to increase the safety of blood component therapy for paediatric patients with malignant disorders without affecting clinical efficacy. A randomized clinical trial including more patients should follow this pilot study to confirm its results.
- 19 February 2019
- Published by Wiley in Vox Sanguinis
- Vol. 114 (3) , 223-231
The pathogen‐reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases
Background: Transmission of pathogens through blood transfusion is still of great concern to clinicians, patients and blood providers. Pathogen reduction technologies (PRT) have been successfully applied for the treatment of labile blood components, such as plasma, platelets and whole blood (WB), which are now used in routine in many countries. We report the clinical evaluation of suspension of red blood cells (RBC‐S) derived from the WB treated with riboflavin and UV light (RF+UV).Study Design and Methods: Seventy paediatric patients (0·3–17·1 years old) suffering from different malignant disorders were recruited and assigned to two groups: the control group (C) received transfusions of γ‐irradiated RBC‐S. The experimental group (T) received RBC‐S derived from WB, treated with RF+UV. Clinical efficacy was evaluated during follow‐up periods by Hb and Ht increments, and needs for transfusion support. Safety was assessed through active surveillance, recording post‐transfusion reactions, anti‐erythrocyte's antibody formation, haptoglobin and serum potassium levels.Results: The clinical efficacy of RBC‐S in both groups was similar: mean post‐transfusion Hb concentration (101·6 ± 7·57 g/l vs. 100 ± 8·3 g/l; P = 0·43), and Ht level (28·5 ± 2·42% vs. 28·2 ± 2·7%; P = 0·66). Transfusion of pathogen‐reduced RBC‐S did not increase the frequency of transfusion reactions and did not induce an excessive immune response in the follow‐up period.Conclusion: Transfusion of RBC‐S, obtained from pathogen‐reduced WB, is a promising method to increase the safety of blood component therapy for paediatric patients with malignant disorders without affecting clinical efficacy. A randomized clinical trial including more patients should follow this pilot study to confirm its results.
- Open Access
- 6 February 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-16
Erythrocytes as bioreactors to decrease excess ammonium concentration in blood
Increased blood ammonium concentrations cause neurological complications. Existing drugs are not always sufficiently effective. Alternatively, erythrocytes-bioreactors (EBRs) loaded with enzymes utilizing ammonium, were suggested for ammonium removal from blood. However all they worked only for a short period of time. The reasons for this were not investigated. In this study, EBR mathematical models were developed and analysed based on the reactions of glycolysis and different enzymes utilizing ammonium, which showed that the efficiency and duration of EBRs’ functioning could be limited due to low permeability of the cell membrane for some key substrates and products. A new enzyme system including glutamate dehydrogenase and alanine aminotransferase was proposed and realised experimentally, which was not limited by cell membrane permeability for glutamate and α-ketoglutarate due to creating metabolic pathway where these metabolites were produced and consumed cyclically. New bioreactors removed ammoniumin vitroat the rate of 1.5 mmol/h × lRBCs(for human bioreactors) andin vivoin a model of hyperammoniemia in mice at the rate of 2.0 mmol/h × lRBCs(for mouse bioreactors), which correlated with model calculations. Experimental studies proved the proposed mathematical models are correct. Mathematical simulation of erythrocyte-bioreactors opens new opportunities for analysing the efficiency of any enzyme included in erythrocytes.
- 6 February 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-16
Open AccessErythrocytes as bioreactors to decrease excess ammonium concentration in blood
Increased blood ammonium concentrations cause neurological complications. Existing drugs are not always sufficiently effective. Alternatively, erythrocytes-bioreactors (EBRs) loaded with enzymes utilizing ammonium, were suggested for ammonium removal from blood. However all they worked only for a short period of time. The reasons for this were not investigated. In this study, EBR mathematical models were developed and analysed based on the reactions of glycolysis and different enzymes utilizing ammonium, which showed that the efficiency and duration of EBRs’ functioning could be limited due to low permeability of the cell membrane for some key substrates and products. A new enzyme system including glutamate dehydrogenase and alanine aminotransferase was proposed and realised experimentally, which was not limited by cell membrane permeability for glutamate and α-ketoglutarate due to creating metabolic pathway where these metabolites were produced and consumed cyclically. New bioreactors removed ammoniumin vitroat the rate of 1.5 mmol/h × lRBCs(for human bioreactors) andin vivoin a model of hyperammoniemia in mice at the rate of 2.0 mmol/h × lRBCs(for mouse bioreactors), which correlated with model calculations. Experimental studies proved the proposed mathematical models are correct. Mathematical simulation of erythrocyte-bioreactors opens new opportunities for analysing the efficiency of any enzyme included in erythrocytes.
- Open Access
- 12 January 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (4)
L-asparaginase: new approaches to improve pharmacological characteristics
The review focuses on the antitumor L-asparaginase preparation, its properties and mechanism of action, as well as its new drug forms, which possess improved characteristics of efficiency, safety and pharmacokinetics. Particular attention is paid to L-asparaginase included in erythrocytes.
- 12 January 2019
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (4)
Open AccessL-asparaginase: new approaches to improve pharmacological characteristics
The review focuses on the antitumor L-asparaginase preparation, its properties and mechanism of action, as well as its new drug forms, which possess improved characteristics of efficiency, safety and pharmacokinetics. Particular attention is paid to L-asparaginase included in erythrocytes.
- 1 January 2019
- Published by AIP Publishing
- Vol. 2140, 020041
Development of a concentration unit for the automated system for incorporating L-asparaginase into human erythrocytes
- 1 January 2019
- Published by AIP Publishing
- Vol. 2140, 020041
Development of a concentration unit for the automated system for incorporating L-asparaginase into human erythrocytes
- Open Access
- 27 October 2018
- Published by Publishing House ABV Press in Oncohematology
- Vol. 13 (3) , 91-101
Comparative methodological studies of L-asparaginase encapsulation into erythrocytes
Background. L-asparaginase is an enzyme, widely used in the therapy of acute lymphoblastic leukemia in children and adults, but its use is limited due to a wide range of side effects and anaphylactic reactions. L-asparaginase loaded into erythrocytes can solve these problems. This enzyme is protected from the immune system and plasma proteases due to erythrocyte membrane, but continues to work inside the cell because its membrane is permeable to L-asparagine. Thus, the half-life of the drug increases and anaphylactic reactions reduce. The encapsulation of L-asparaginase into erythrocytes can be performed by various osmotic methods. Each of them is characterized by the amount of encapsulated enzyme, the cell yield, as well as by the quality indices of the survived erythrocytes. An important parameter of each method is the possibility to provide sterility of this dosage form for the clinical use.The aim of the study was the comparing of three osmotic methods of L-asparaginase encapsulation into erythrocytes (hypo-osmotic lysis, dialysis and flow dialysis) to select the most promising method for clinical use.Materials and methods. A suspension of erythrocytes of healthy donors (hematocrit 60–70%) was mixed with L-asparaginase from E. сoli. The procedures of hypotonic reversible lysis, dialysis in dialysis bags, or flow dialysis using pediatric dialyzers were performed. The physiological osmolality was restored in suspensions after the procedure by the addition of a hypertonic solution, and they were incubated for 30 min at 37 °C. Then the cells were washed in isotonic phosphate-buffered saline with pH 7.4. Activity of L-asparaginase, volume, hematocrit, hematological indices and osmotic cell fragility of erythrocytes were measured in the suspensions of erythrocytes before and after the enzyme encapsulation procedure.Results. An optimal osmolality of the hypotonic buffer for each method was selected and was equal to 90–110 mOsm/kg. The yields of encapsulation were 4.2 ± 2.0, 6.0 ± 2.3 and 16.2 ± 2.2 % for hypotonic lysis, dialysis and flow dialysis, respectively. The hematological indices of the obtained erythrocyte-carriers differed from the corresponding parameters of the initial erythrocytes, but did not differ significantly for different methods.Conclusion. Comparative investigation of mentioned above parameters allowed choosing the method of flow dialysis as the most promising for clinical use.
- 27 October 2018
- Published by Publishing House ABV Press in Oncohematology
- Vol. 13 (3) , 91-101
Open AccessComparative methodological studies of L-asparaginase encapsulation into erythrocytes
Background. L-asparaginase is an enzyme, widely used in the therapy of acute lymphoblastic leukemia in children and adults, but its use is limited due to a wide range of side effects and anaphylactic reactions. L-asparaginase loaded into erythrocytes can solve these problems. This enzyme is protected from the immune system and plasma proteases due to erythrocyte membrane, but continues to work inside the cell because its membrane is permeable to L-asparagine. Thus, the half-life of the drug increases and anaphylactic reactions reduce. The encapsulation of L-asparaginase into erythrocytes can be performed by various osmotic methods. Each of them is characterized by the amount of encapsulated enzyme, the cell yield, as well as by the quality indices of the survived erythrocytes. An important parameter of each method is the possibility to provide sterility of this dosage form for the clinical use.The aim of the study was the comparing of three osmotic methods of L-asparaginase encapsulation into erythrocytes (hypo-osmotic lysis, dialysis and flow dialysis) to select the most promising method for clinical use.Materials and methods. A suspension of erythrocytes of healthy donors (hematocrit 60–70%) was mixed with L-asparaginase from E. сoli. The procedures of hypotonic reversible lysis, dialysis in dialysis bags, or flow dialysis using pediatric dialyzers were performed. The physiological osmolality was restored in suspensions after the procedure by the addition of a hypertonic solution, and they were incubated for 30 min at 37 °C. Then the cells were washed in isotonic phosphate-buffered saline with pH 7.4. Activity of L-asparaginase, volume, hematocrit, hematological indices and osmotic cell fragility of erythrocytes were measured in the suspensions of erythrocytes before and after the enzyme encapsulation procedure.Results. An optimal osmolality of the hypotonic buffer for each method was selected and was equal to 90–110 mOsm/kg. The yields of encapsulation were 4.2 ± 2.0, 6.0 ± 2.3 and 16.2 ± 2.2 % for hypotonic lysis, dialysis and flow dialysis, respectively. The hematological indices of the obtained erythrocyte-carriers differed from the corresponding parameters of the initial erythrocytes, but did not differ significantly for different methods.Conclusion. Comparative investigation of mentioned above parameters allowed choosing the method of flow dialysis as the most promising for clinical use.
- Open Access
- 9 February 2018
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (1)
Comparison of laboratory parameters of X-ray irradiated erythrocyte suspensions and suspensions, prepared from whole blood pre-treated with ultraviolet in the presence of riboflavin
- 9 February 2018
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (1)
Open AccessComparison of laboratory parameters of X-ray irradiated erythrocyte suspensions and suspensions, prepared from whole blood pre-treated with ultraviolet in the presence of riboflavin
- Open Access
- 9 February 2018
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (1)
Erythrocyte: а bag with hemoglobin, or a living active cell?
The review concerns the oxygen transfer in the body and the role of erythrocytes in this process. The mechanisms of regulation of hemoglobin-oxygen binding are described, as well as the effect of erythrocytes shape on blood rheology.
- 9 February 2018
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 17 (1)
Open AccessErythrocyte: а bag with hemoglobin, or a living active cell?
The review concerns the oxygen transfer in the body and the role of erythrocytes in this process. The mechanisms of regulation of hemoglobin-oxygen binding are described, as well as the effect of erythrocytes shape on blood rheology.